New hope for rare eye cancer: drug targets tumors with DNA tracking

NCT ID NCT06070012

Recruiting now Disease control Sponsor: Diwakar Davar Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called tebentafusp in people with a specific type of advanced eye cancer (uveal melanoma) that has spread to other parts of the body. The drug is designed to help the immune system attack cancer cells. Researchers will also use a blood test to measure tumor DNA and see how well the treatment works. About 44 people with a certain genetic marker (HLA-A*0201) who have not had prior treatment for their metastatic cancer will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UVEAL MELANOMA

Contacts and locations

Locations

Georgetown University Medical Center
RECRUITING

Washington D.C., District of Columbia, 20007, United States
UPMC Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
University of Colorado Cancer Center
RECRUITING

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.